KNSA vs. GMTX, ANIP, AKRO, GYRE, MORF, PCRX, DVAX, DAWN, AVDL, and XNCR
Should you be buying Kiniksa Pharmaceuticals stock or one of its competitors? The main competitors of Kiniksa Pharmaceuticals include Gemini Therapeutics (GMTX), ANI Pharmaceuticals (ANIP), Akero Therapeutics (AKRO), Gyre Therapeutics (GYRE), Morphic (MORF), Pacira BioSciences (PCRX), Dynavax Technologies (DVAX), Day One Biopharmaceuticals (DAWN), Avadel Pharmaceuticals (AVDL), and Xencor (XNCR). These companies are all part of the "pharmaceutical preparations" industry.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, community ranking, valuation and institutional ownership.
Kiniksa Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.
54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are held by institutional investors. 54.6% of Kiniksa Pharmaceuticals shares are held by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Gemini Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals' return on equity of -7.26% beat Gemini Therapeutics' return on equity.
Kiniksa Pharmaceuticals received 147 more outperform votes than Gemini Therapeutics when rated by MarketBeat users. Likewise, 64.34% of users gave Kiniksa Pharmaceuticals an outperform vote while only 63.33% of users gave Gemini Therapeutics an outperform vote.
Kiniksa Pharmaceuticals has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kiniksa Pharmaceuticals had 3 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals and 0 mentions for Gemini Therapeutics. Kiniksa Pharmaceuticals' average media sentiment score of 0.47 beat Gemini Therapeutics' score of 0.00 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the media.
Kiniksa Pharmaceuticals presently has a consensus target price of $31.00, suggesting a potential upside of 56.80%. Given Kiniksa Pharmaceuticals' higher probable upside, equities analysts clearly believe Kiniksa Pharmaceuticals is more favorable than Gemini Therapeutics.
Summary
Kiniksa Pharmaceuticals beats Gemini Therapeutics on 15 of the 16 factors compared between the two stocks.
Get Kiniksa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kiniksa Pharmaceuticals Competitors List
Related Companies and Tools
